X

Drug Profile

Research programme: small molecule therapeutics - Neuron23

Latest Information Update: 01 Jan 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neuron23; Origenis
Class Antiparkinsonians; Small molecules
Mechanism of Action LRRK2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Parkinson's disease

Highest Development Phases

Preclinical Parkinson's disease

Most Recent Events

01 Jan 2021 Small molecule therapeutics - Neuron23 is available for licensing as of 01 Jan 2021. https://neuron23.com/partners/ (Neuron23 pipeline, December 2020)
16 Dec 2020 Neuron23 and Origenis agree to co-develop five small molecule therapeutics for Parkinson's disease (Neuron23 pipeline, December 2020)
16 Dec 2020 Preclinical trials in Parkinson's disease in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com